Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial

Phase II RCT (n=147) investigating use of perioperative chemotherapy found and overall survival rate of 47% for mFOLFIRINOX and 48% for gemcitabine/nab-paclitaxel, which were found not to be superior to the historical trial data for use of adjuvant chemotherapy

JAMA Oncology